This poster is published under an open license
. Please read the disclaimer
for further details.
Neoplasia, Image verification, Cancer, Diagnostic procedure, Contrast agent-intravenous, Ultrasound, PET-CT, Mammography, Oncology, Nuclear medicine, Breast
R. Battista1, S. Panareo2, V. Marchesi1, A. Pecchi1, B. Canossi1, P. Torricelli1; 1Modena/IT, 2Ferrara/IT
Aims and objectives
Whole body positron emission tomography/computed tomography (PET/CT) with fluorine 18 fluorodeoxyglucose (18F-FDG) has been used successfully and with increasing frequency in the evaluation and clinical management of an expanding number of neoplasms.
As widespread clinical application increases,
unexpected radiographic findings are occasionally identified.
These incidental findings are often suspicious for a second primary malignancy.
in patients with a known or suspected primary malignancy,
additional primary cancer has been found in 1,7-31,0% of cases .
Although the sensitivity of 18F-FDG PET/CT in identifying primary breast tumors varies from 25% to 80%,
the specificity is more consistent from 95% to 98% .
physiological breast 18F-FDG uptake may also be seen,
e.g. in lactation,
in the presence of breast implants and focally in certain benign breast lesions .
Previous studies have reported an incidence of malignancy of between 37,5% and 83,0% in incidental focal 18F-FDG breast uptake [4-6],
that suggest to examine this finding.
The aim of this study was to determine the clinical-diagnostic significance of incidental finding of hypermetabolic foci in the breast at 18F-FDG PET/CT in patients with malignant disease other than breast cancer,
correlating this finding with conventional imaging modalities and histopathology,